Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

OptimizeRx (OPRX) Income towards Parent Company: 2010-2025

Historic Income towards Parent Company for OptimizeRx (OPRX) over the last 16 years, with Q3 2025 value amounting to $779000.0.

  • OptimizeRx's Income towards Parent Company rose 10853.79% to $779000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.8 million, marking a year-over-year increase of 11520.25%. This contributed to the annual value of -$15.3 million for FY2024, which is 1282.02% up from last year.
  • Latest data reveals that OptimizeRx reported Income towards Parent Company of $779000.0 as of Q3 2025, which was up 10853.79% from $1.5 million recorded in Q2 2025.
  • Over the past 5 years, OptimizeRx's Income towards Parent Company peaked at $4.7 million during Q4 2024, and registered a low of -$11.7 million during Q4 2023.
  • For the 5-year period, OptimizeRx's Income towards Parent Company averaged around -$2.7 million, with its median value being -$2.9 million (2023).
  • As far as peak fluctuations go, OptimizeRx's Income towards Parent Company crashed by 879000.85% in 2022, and later soared by 14018.74% in 2024.
  • Over the past 5 years, OptimizeRx's Income towards Parent Company (Quarter) stood at $623462.0 in 2021, then tumbled by 152.26% to -$325836.0 in 2022, then plummeted by 3503.04% to -$11.7 million in 2023, then surged by 140.19% to $4.7 million in 2024, then tumbled by 83.49% to $779000.0 in 2025.
  • Its last three reported values are $779000.0 in Q3 2025, $1.5 million for Q2 2025, and -$2.2 million during Q1 2025.